Results 91 to 100 of about 2,912 (169)

Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. [PDF]

Mediterr J Hematol Infect Dis
Marzi F, Alessandri M, De Crescenzo V, Del Vecchio S, Radi S, Manini M.   +5 more
europepmc   +1 more source

Complete genome sequences of KPC-producing <i>Klebsiella pneumoniae</i> isolates pre- and post-development of meropenem/vaborbactam resistance. [PDF]

Microbiol Resour Announc
Ozer EA, Nozick SH, Singh N, Watkins JV, Hauser AR, Bulman ZP.   +5 more
europepmc   +1 more source

Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing <i>Klebsiella pneumoniae</i> in the hollow fiber infection model. [PDF]

Antimicrob Agents Chemother
Singh N, Jogan CML, Zang Y, Shan X, Lang Y, Karunanidhi A, Watkins JV, Curry BN, Tamma PD, Nozick SH, Ozer EA, Hauser AR, Bulitta JB, Bulman ZP.   +13 more
europepmc   +1 more source

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance. [PDF]

Antibiotics (Basel), 2023
Duda-Madej A, Viscardi S, Topola E.
europepmc   +1 more source

Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam. [PDF]

BMC Infect Dis
Li Y, Li Y, Jia X, Mao H, Li D, Zhang J.
europepmc   +1 more source

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant <i>Enterobacter cloacae</i>. [PDF]

Antimicrob Agents Chemother
Lavoie T, Sierra T, Daffinee K, Pogue JM, Achour B, LaPlante K.   +5 more
europepmc   +1 more source

Emergence of KPC-producing <i>Pseudomonas aeruginosa</i> in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam. [PDF]

Antimicrob Agents Chemother
Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, Taltavull B, Tarriño-León M, Gallardo-García MdM, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, Moscoso M, Beceiro A, Oliver A, Bou G, Arca-Suárez J.   +13 more
europepmc   +1 more source

In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis

Journal of Antimicrobial Chemotherapy, 2019
Wesley D Kufel, Ambika P Eranki, Kristopher M Paolino, Andrea Call, Christopher D Miller, Bryan T Mogle   +5 more
openaire   +2 more sources

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. [PDF]

Eur J Clin Microbiol Infect Dis, 2023
Nordmann P, Bouvier M, Poirel L.
europepmc   +1 more source

Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. [PDF]

Antimicrob Agents Chemother
Mohammad S, Al Namer Y, Rahimeh W, Albalas M, Almangour TA.   +4 more
europepmc   +1 more source